Details

Autor(en) / Beteiligte

• Rodenhuis, Sjoerd
• Bontenbal, Marijke
• Beex, Louk V.A.M
• Wagstaff, John
• Richel, Dick J
• Nooij, Marianne A
• Voest, Emile E
• Hupperets, Pierre
• van Tinteren, Harm
• Peterse, Hans L
• TenVergert, Elisabeth M
• de Vries, Elisabeth G.E

Titel

High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer

Ist Teil von

• The New England journal of medicine, 2003-07, Vol.349 (1), p.7-16

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2003

Quelle

MEDLINE

Beschreibungen/Notizen

• The efficacy of high-dose chemotherapy plus hematopoietic stem-cell rescue for breast cancer with axillary-lymph-node metastases was tested in a multicenter randomized trial. The advantage of the aggressive treatment over conventional therapy was marginal and was confined to women whose tumors expressed little or no HER2/ neu . The advantage of aggressive treatment was marginal. A number of relatively small, uncontrolled studies have suggested that adjuvant high-dose chemotherapy with hematopoietic progenitor-cell infusion could be of benefit for high-risk breast cancer. 1 The largest of these studies suggested that high-dose chemotherapy dramatically prolongs progression-free survival as compared with survival among historical controls who had received conventional therapy. 2 We and others were not able to reproduce this result. 3 Clearly, much larger prospective, controlled studies were required to ascertain the efficacy of this treatment. The Dutch randomized study reported here was designed in 1993, and the original protocol included fewer than 300 patients. When the study had been under . . .